Inmune Bio, Inc.

Inmune Bio, Inc. (ticker: INMB) is an NASDAQ-listed biological products, (no diagnostic substances) company. DredgeCap's structured extraction of INMB's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. INMB reported $50K in revenue and -$5.41M for the period ending 2025-12-31, with operating cash flow of -$3.40M. Cash and equivalents stood at $21.36M (up 10.5% year-over-year). Total assets of $25.82M exceed total liabilities of $6.19M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.

INMB Cash Runway

Months-of-runway analysis for INMB, derived directly from SEC XBRL: latest cash and operating cash flow, monthly burn rate, runway under current conditions. Historical trend + verbatim citation panel ships in Phase 2.

Coming in Phase 2

The dedicated per-ticker cash-runway page will surface a 6-8 quarter trend with the underlying us-gaap:CashAndCashEquivalentsAtCarryingValue + us-gaap:NetCashProvidedByUsedInOperatingActivities citations alongside each data point. In the meantime, see the ranked cross-company view:

All companies ranked by months-of-runway →

Related on INMB

Share-count dilution →

Dilution is the natural counterpart to runway burn.

Going-concern history →

Auditor + management language across filings.